Human cathelicidin antimicrobial peptide
PRODUCT PROFILE
LL-37
£59.00
LL-37 is human cathelicidin antimicrobial peptide. Researchers examine it in relation to innate host defence, microbial membranes, inflammation and wound signalling.
Why it is distinct
Direct antimicrobial membrane activity separates it from immune regulators such as KPV or thymosin alpha-1.
- Evidence stageEarly human evidence
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
LL-37 is human cathelicidin antimicrobial peptide. Researchers examine it in relation to innate host defence, microbial membranes, inflammation and wound signalling.
Research focus+
Researchers study how it interacts with microbes, inflammation and wound repair. Its effects are complex—it may help defence in some settings but can also increase inflammation in others.
How the mechanism differs+
Can disrupt microbial membranes and also signal through host immune pathways; activity is context- and concentration-dependent.
Evidence and limitations+
Strong mechanistic and preclinical literature with limited early clinical exploration; inflammatory effects can be bidirectional.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study how it interacts with microbes, inflammation and wound repair. Its effects are complex—it may help defence in some settings but can also increase inflammation in others.
Can disrupt microbial membranes and also signal through host immune pathways; activity is context- and concentration-dependent.
Direct antimicrobial membrane activity separates it from immune regulators such as KPV or thymosin alpha-1.
Strong mechanistic and preclinical literature with limited early clinical exploration; inflammatory effects can be bidirectional.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Bronchogen
£46.0020 mgBatch file pendingAirway-tissue focus rather than VIP’s defined VPAC-receptor bronchodilatory biology.
UnavailableAsk about availability -
Established
Thymosin Alpha-1
£69.0010 mgBatch file pendingAn immune-response modulator with human clinical literature, distinct from LL-37’s direct antimicrobial activity.
UnavailableAsk about availability -
Experimental
Vilon
£46.0020 mgBatch file pendingA minimal dipeptide bioregulator, much smaller and less mechanistically defined than thymosin alpha-1.
UnavailableAsk about availability -
Clinical research
VIP
Price range: £29.99 through £38.995 mgBatch file pendingA receptor-defined pleiotropic neuropeptide with direct vasodilatory and bronchodilatory effects.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page